| __timestamp | Blueprint Medicines Corporation | Novavax, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 19928000 |
| Thursday, January 1, 2015 | 14456000 | 30842000 |
| Friday, January 1, 2016 | 19218000 | 46527000 |
| Sunday, January 1, 2017 | 27986000 | 34451000 |
| Monday, January 1, 2018 | 47928000 | 34409000 |
| Tuesday, January 1, 2019 | 96388000 | 34417000 |
| Wednesday, January 1, 2020 | 157743000 | 145290000 |
| Friday, January 1, 2021 | 195293000 | 298358000 |
| Saturday, January 1, 2022 | 237374000 | 488691000 |
| Sunday, January 1, 2023 | 295141000 | 468946000 |
| Monday, January 1, 2024 | 359272000 |
Unleashing the power of data
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Blueprint Medicines Corporation and Novavax, Inc. have shown distinct trajectories in their SG&A spending from 2014 to 2023. Blueprint Medicines started with modest expenses, but by 2023, their SG&A costs surged by over 3,600%, reflecting their aggressive expansion and investment in new therapies. Meanwhile, Novavax, known for its vaccine development, saw a staggering increase of over 2,250% in the same period, peaking in 2022. This spike aligns with their pivotal role in the global health landscape during the COVID-19 pandemic. These trends highlight the dynamic nature of biotech financial strategies, where spending is often a precursor to innovation and market leadership. As these companies continue to evolve, their financial strategies will be key indicators of their future success.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Novavax, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Blueprint Medicines Corporation Trends and Insights
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and PTC Therapeutics, Inc.
Blueprint Medicines Corporation and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Blueprint Medicines Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Alpine Immune Sciences, Inc. and Novavax, Inc.
Breaking Down SG&A Expenses: MorphoSys AG vs Novavax, Inc.
Mesoblast Limited vs Novavax, Inc.: SG&A Expense Trends
Wave Life Sciences Ltd. and Novavax, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Dynavax Technologies Corporation and Novavax, Inc.